Upstream Bio Company Insiders
| UPB Stock | 8.38 -0.28 -3.23% |
Upstream Bio employs about 52 people. The company is managed by 16 executives with a total tenure of roughly 122 years, averaging almost 7.0 years of service per executive, having 3.25 employees per reported executive. A leadership review of Upstream Bio matters because management quality often shapes how effectively strategy is translated into revenue growth, margins, and cash generation. That matters because management quality often influences how well a company responds when business conditions become less favorable.
Upstream | Build portfolio with Upstream Stock |
Management Team Effectiveness
The company has Return on Asset of -28.15 % which implies that asset efficiency is currently in negative territory. This is substantially below the peer group. In the same way, it shows a return on shareholders' equity (ROE) of -40.8 %, which indicates that stockholders experienced a net loss on invested capital.As of last month (February 2026), Common Stock Shares Outstanding is forecasted to soften to approximately 45.5 M.
Insider Trading Activities
Tracking Upstream Bio's insider filings adds context. Executives often respond to business conditions well before market sentiment shifts. It trades on NASDAQ in US. The business currently sits in the Healthcare sector and the Biotechnology industry.
Houghton Adam few days ago Disposition of 699 shares by Houghton Adam of Upstream Bio at 9.29 subject to Rule 16 b-3 | ||
Sutherland Everett Rand over two months ago Acquisition by Sutherland Everett Rand of 225000 shares of Upstream Bio at 27.07 subject to Rule 16 b-3 | ||
Sutherland Everett Rand over two months ago Acquisition by Sutherland Everett Rand of 75000 shares of Upstream Bio subject to Rule 16 b-3 | ||
Ratcliffe Liam over six months ago Acquisition by Ratcliffe Liam of 17096 shares of Upstream Bio, at 11.59 subject to Rule 16 b-3 |
Outstanding Bonds
Outstanding bonds linked to Upstream Bio can tell investors a great deal about how the company finances itself beyond common equity markets. Current market capitalization is about 1.26 Billion. Bond investors and equity investors often care about the same cash flows, but they rank the risks differently.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Corporate Filings
F4 | 17th of March 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 11th of February 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2025 An amended filing to the original Schedule 13G | ViewVerify |
8K | 5th of November 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 24th of October 2025 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 2nd of September 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 6th of August 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Holders Distribution
A large institutional presence around Upstream Bio deserves attention because well-resourced investors can establish or unwind positions quickly enough to change the market character of the security. One practical risk is that institutions can own millions of shares, so concentrated selling can pressure the stock quickly once sentiment changes.
Market Cap and Value
Workforce Comparison
Upstream Bio is rated below average in number of employees among leading competitors. The total workforce of Health Care industry is at this time estimated at about 2,530. Upstream Bio holds roughly 52.0 in number of employees claiming about 2.06% of equities under Health Care sector.
Insider Trading History
Upstream Bio's insider log provides a timeline of management conviction alongside earnings and guidance changes. Investors focus on trades outside normal pay timelines, as those are more likely to reflect genuine conviction.
Notable Stakeholders
An Upstream Bio stakeholder is any individual or group with an interest in the outcome of the business, which is why stakeholder analysis can reveal who may influence strategy and oversight. The stronger interpretation comes from connecting stakeholder presence with management behavior, governance patterns, and changes in the operating story.
| MD MPH | CEO Director | Profile | |
| MPH MD | CEO Director | Profile | |
| Meggan Buckwell | Director Relations | Profile | |
| Allison JD | General VP | Profile | |
| Sumathi MD | VP Development | Profile | |
| Aaron MD | Chief Development | Profile | |
| Adam MBA | Chief Officer | Profile | |
| Parika MS | Head Operations | Profile | |
| Maryse MS | Senior Writing | Profile | |
| Allison Ambrose | General Counsel | Profile | |
| Stacy MS | Chief Officer | Profile | |
| PMP MS | Chief Officer | Profile | |
| Fang Xie | Vice Biometrics | Profile | |
| Mersedeh PharmD | Senior Quality | Profile | |
| Lisa Fiering | Senior Culture | Profile | |
| William Collins | Secretary | Profile |
Management Information & Data Sources
Upstream Bio is a small-cap company in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Executive review focuses on insiders, senior management, and employee signals. Leadership review helps frame whether management actions match reported operating results. CEO is MD MPH with 52 employees and 16 reported executives.
Reported values for Upstream Bio are derived from periodic company reporting and market reference feeds and then standardized by Macroaxis analytics. Analyst projections are included when active coverage applies. Refresh times depend on source availability. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Michael Smolkin - Member of Macroaxis Board of DirectorsWorkforce Efficiency and Productivity
Manpower analysis for Upstream Bio matters because revenue per employee and profit per employee can reveal shifts in productivity and operating discipline. A disciplined workforce review can reveal whether execution quality is improving beneath the top-line numbers.
Upstream Bio Manpower Efficiency
Return on Upstream Bio Manpower
| Revenue Per Employee | 45.6K | |
| Revenue Per Executive | 148.1K | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 3.9M | |
| Working Capital Per Employee | 9M | |
| Working Capital Per Executive | 29.3M |
Popular Tools for Upstream Stock analysis
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |